Evidence map›Paper›PMID 35735442›Full record

ArticleCurrent oncology (Toronto, Ont.)2022

A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a

Brieuc Sautois, Andrea Loehr, Simon P Watkins, Hélène Schroeder, Wassim Abida

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Brieuc SautoisMedical Oncology, University Hospital of Liège, CHU Sart Tilman, 4000 Liège, Belgium.ORCID 0000-0002-0029-7735
Andrea LoehrTranslational Medicine, Clovis Oncology Inc., Boulder, CO 08006, USA.
Simon P WatkinsClinical Science, Clovis Oncology UK, Ltd., Cambridge CB21 6GP, UK.ORCID 0000-0001-8628-8399
Hélène SchroederMedical Oncology, University Hospital of Liège, CHU Sart Tilman, 4000 Liège, Belgium.ORCID 0000-0002-0219-0755
Wassim AbidaGenitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Centre Hospitalier Universitaire de Liège · BEClovis Oncology (United Kingdom) · GBClovis Oncology (United States) · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
SPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Yu Chen, MICHAEL J MORRIS · 2001 to 2026
$63.0M
NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA092629
6 · The paper itself

Abstract

PARP inhibitors, such as rucaparib, have been well characterized in metastatic castration-resistant prostate cancer (mCRPC) associated with BRCA alterations, and the clinical activity of these agents has also been evaluated in patients with mCRPC associated with alterations in other non-BRCA DNA damage repair (DDR) genes, including

Indexed as

Circulating Tumor DNAProstatic Neoplasms, Castration-ResistantDNA-Binding ProteinsHumansIndolesMalePoly(ADP-ribose) Polymerase InhibitorsProstate-Specific AntigenCirculating Tumor DNADNA-Binding ProteinsIndolesPoly(ADP-ribose) Polymerase InhibitorsProstate-Specific AntigenRAD51B protein, humanrucaparibPARP inhibitorsprostate cancerRAD51B

Identifiers

PMID35735442
PMCPMC9221801
OpenAlexW4281759436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.